Skip to main content

Table 3 Multivariate analysis for OHA classes pre and post CDA 2008 guidelines

From: Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines

  No (%) of patients or mean ± SD Multivariate analysis*
  Pre Post OR (95% CI) p value
n = 670 n = 609
Classes of OHA     
• Metformin ± other 601 (89.7) 576 (94.6) 1.00 [Reference]  
• TZD 18 (2.7) 3 (0.5) 0.21 (0.08-0.55) 0.001
• Sulfonylurea 54 (8.1) 27 (4.4) 0.68 (0.43-1.09) 0.11
• Other 3 (0.5) 4 (0.7) 1.44 (0.29-7.06) 0.65
  1. Note: OHA Oral hypoglycemic agent, TZD Thiazolidinediones, CDA Canadian Diabetes Association.
  2. *Multivariate analysis done for patients’ gender, age and co-morbidities, guidelines, MD evidence scale, gender, practice experience and drugs.
  3. Patients initiated on more than 1 drug (with no Metformin) were counted in both classes.
  4. Includes Alpha-1 glucosidase inhibitor (Acarbose), DPP-4 inhibitor (Sitagliptin) and Meglitinides.